AN2 Therapeutics, Inc. (ANTX) insider trading.
In Q3 2026, insiders at AN2 Therapeutics, Inc. reported 16 non-derivative transactions on 12 Forms 3, 4 and 5: 1 open-market purchase worth $12K and 10 sales worth $343K.
- Transactions
- 16
- Purchases (P)
- 1
- Sales (S)
- 10
- Net shares, P minus S
- -56,748
- Insiders
- 9
- Last filed
- 2026-09-16
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Readnour Robin Shane | Director | 8 | 0 | 8 |
| Trenor Cameron C. III | Officer · Chief Medical Officer | 1 | 0 | 0 |
| Williams Sarah Joanne | Officer · Principal Accounting Officer | 1 | 0 | 1 |
| FitzPatrick Margaret M | Director | 1 | 1 | 0 |
| Zakrzewski Joseph S | Director | 1 | 0 | 0 |
| Martin Patricia A. | Director | 1 | 0 | 0 |
| Marks Gilbert Lynn | Director | 1 | 0 | 0 |
| Aziz Kabeer | Director | 1 | 0 | 0 |
| Eizen Joshua M | Officer · See Remarks | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Trenor Cameron C. III | A (A) | 116,667 | $0 | 116,667 | Form 4 |
| 2026-09-09 | Readnour Robin Shane | S (D) | 585 | $6.02 | 624,765 | Form 4 |
| 2026-09-09 | Readnour Robin Shane | S (D) | 523 | $6.02 | 557,467 | Form 4 |
| 2026-09-08 | Readnour Robin Shane | S (D) | 4,725 | $6.02 | 557,990 | Form 4 |
| 2026-09-08 | Readnour Robin Shane | S (D) | 5,294 | $6.02 | 625,350 | Form 4 |
| 2026-09-03 | Readnour Robin Shane | S (D) | 2,877 | $6.07 | 562,715 | Form 4 |
| 2026-09-03 | Readnour Robin Shane | S (D) | 3,223 | $6.07 | 630,644 | Form 4 |
| 2026-09-01 | Williams Sarah Joanne | S (D) | 272 | $5.53 | 66,311 | Form 4 |
| 2026-09-01 | FitzPatrick Margaret M | P (A) | 2,098 | $5.53 | 10,708 | Form 4 |
| 2026-08-17 | Readnour Robin Shane | S (D) | 16,696 | $6.01 | 565,592 | Form 4 |
| 2026-08-17 | Readnour Robin Shane | S (D) | 18,706 | $6.01 | 633,867 | Form 4 |
| 2026-08-14 | Zakrzewski Joseph S | G (D) | 405,880 | $0 | 0 | Form 4 |
| 2026-07-10 | Martin Patricia A. | A (A) | 766 | $0 | 18,863 | Form 4 |
| 2026-07-10 | Marks Gilbert Lynn | A (A) | 2,789 | $0 | 81,873 | Form 4 |
| 2026-07-10 | Aziz Kabeer | A (A) | 2,852 | $0 | 59,106 | Form 4 |
| 2026-07-08 | Eizen Joshua M | S (D) | 5,945 | $4.17 | 206,554 | Form 4 |
Transaction codes in this quarter
Get ANTX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1880438&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · ANTX company page · AN2 Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling AN2 Therapeutics, Inc. (ANTX)?
In Q3 2026, insiders at AN2 Therapeutics, Inc. reported 16 non-derivative transactions on 12 Forms 3, 4 and 5: 1 open-market purchase worth $12K and 10 sales worth $343K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these AN2 Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/antx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.